{"id":31792,"date":"2025-04-15T12:59:30","date_gmt":"2025-04-15T04:59:30","guid":{"rendered":"https:\/\/flcube.com\/?p=31792"},"modified":"2025-04-15T12:59:31","modified_gmt":"2025-04-15T04:59:31","slug":"chromatin-bioscience-collaborates-with-astellas-pharma-to-design-cell-selective-synthetic-promoters","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31792","title":{"rendered":"Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters"},"content":{"rendered":"\n

UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503<\/a>) to design cell-selective synthetic promoters aligned with Astellas’ target profile. The partnership leverages Chromatin’s proprietary chromatinLENS platform to achieve highly precise and durable gene expression in specific cell types, marking a significant step forward in gene therapy innovation.<\/p>\n\n\n\n

Collaboration Objectives<\/strong>
The collaboration focuses on utilizing the chromatinLENS platform to identify gene regulatory elements from the dark genome and design synthetic promoters tailored to Astellas’ specific requirements. These promoters are expected to enable precise control over gene expression, enhancing the efficacy and safety of therapeutic applications.<\/p>\n\n\n\n

ChromatinLENS Platform: Broad Applications<\/strong>
The chromatinLENS platform is a versatile tool applicable across multiple industries, including therapeutics, agritech, industrial biotechnology, and bioprocessing. Its ability to identify and design gene regulatory elements from underutilized genomic regions offers unprecedented opportunities for innovation in gene-based technologies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503)…<\/p>\n","protected":false},"author":1,"featured_media":31801,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[353,3998,1177],"class_list":["post-31792","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-astellas-pharma","tag-chromatin-bioscience","tag-tyo-4503"],"yoast_head":"\nChromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503) to design cell-selective synthetic promoters aligned with Astellas' target profile. The partnership leverages Chromatin's proprietary chromatinLENS platform to achieve highly precise and durable gene expression in specific cell types, marking a significant step forward in gene therapy innovation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31792\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters\" \/>\n<meta property=\"og:description\" content=\"UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503) to design cell-selective synthetic promoters aligned with Astellas' target profile. The partnership leverages Chromatin's proprietary chromatinLENS platform to achieve highly precise and durable gene expression in specific cell types, marking a significant step forward in gene therapy innovation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31792\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T04:59:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-15T04:59:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1501-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31792#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31792\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters\",\"datePublished\":\"2025-04-15T04:59:30+00:00\",\"dateModified\":\"2025-04-15T04:59:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31792\"},\"wordCount\":158,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31792#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1501-png.webp\",\"keywords\":[\"Astellas Pharma\",\"Chromatin Bioscience\",\"TYO: 4503\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31792#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31792\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31792\",\"name\":\"Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31792#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31792#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1501-png.webp\",\"datePublished\":\"2025-04-15T04:59:30+00:00\",\"dateModified\":\"2025-04-15T04:59:31+00:00\",\"description\":\"UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503) to design cell-selective synthetic promoters aligned with Astellas' target profile. The partnership leverages Chromatin's proprietary chromatinLENS platform to achieve highly precise and durable gene expression in specific cell types, marking a significant step forward in gene therapy innovation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31792#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31792\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31792#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1501-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1501-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31792#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters - Insight, China's Pharmaceutical Industry","description":"UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503) to design cell-selective synthetic promoters aligned with Astellas' target profile. The partnership leverages Chromatin's proprietary chromatinLENS platform to achieve highly precise and durable gene expression in specific cell types, marking a significant step forward in gene therapy innovation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31792","og_locale":"en_US","og_type":"article","og_title":"Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters","og_description":"UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503) to design cell-selective synthetic promoters aligned with Astellas' target profile. The partnership leverages Chromatin's proprietary chromatinLENS platform to achieve highly precise and durable gene expression in specific cell types, marking a significant step forward in gene therapy innovation.","og_url":"https:\/\/flcube.com\/?p=31792","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-15T04:59:30+00:00","article_modified_time":"2025-04-15T04:59:31+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1501-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31792#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31792"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters","datePublished":"2025-04-15T04:59:30+00:00","dateModified":"2025-04-15T04:59:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31792"},"wordCount":158,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31792#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1501-png.webp","keywords":["Astellas Pharma","Chromatin Bioscience","TYO: 4503"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31792#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31792","url":"https:\/\/flcube.com\/?p=31792","name":"Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31792#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31792#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1501-png.webp","datePublished":"2025-04-15T04:59:30+00:00","dateModified":"2025-04-15T04:59:31+00:00","description":"UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503) to design cell-selective synthetic promoters aligned with Astellas' target profile. The partnership leverages Chromatin's proprietary chromatinLENS platform to achieve highly precise and durable gene expression in specific cell types, marking a significant step forward in gene therapy innovation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31792#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31792"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31792#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1501-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1501-png.webp","width":1080,"height":608,"caption":"Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31792#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1501-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31792"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31792\/revisions"}],"predecessor-version":[{"id":31802,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31792\/revisions\/31802"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31801"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}